Hokudo Co.,Ltd. provides integrated non-clinical study, from study designing to data delivery. They provide high-quality data for evaluating drug efficacy, pharmacology, and safety study.
Hokudo Co.,Ltd. offers a wide range of disease models; spinal cord injury, COPD, atopic dermatitis, hair growth, pain, inflammation, diabetes, and anti-aging. They offer various animal species, rodents(rats, mice), larger animals(pigs, sheep, rabbits)—allowing study designs tailored to diverse research needs.
They offer flexible study design for complex pharmacological studies with well-integrated platform.
Hokudo Co.,Ltd. provides mutagenicity assessments such as bacterial reverse mutation test and chromosomal aberration test, as well as general toxicity testing (acute, subacute, dermal corrosion, sensitization, and eye irritation).
They perform simulated use testing for medical devices such as artificial bones and joints. This offers integrated safety evaluations for both pharmaceuticals and medical devices.
Hokudo Co.,Ltd. accommodates flexible arrangements to meet client needs—full study outsourcing, partial contracts, where clients handle administration or surgery while Hokudo Co.,Ltd. manages husbandry, observation, or support tasks.
Their facilities are also available for rental laboratories for those who might need a specialized set-up or for surgical training purposes. They support a wide spectrum of research and development targets.
Hokudo Co.,Ltd. provides pharmacological study in COPD model.
This model is induced by smoking exposure or bronchitis-like inflammation.
It can reproduce COPD features such as airway inflammation, alveolar destruction, and reduced lung function.
It enables multi-parameter evaluation of drug efficacy by disease progression and is applicable to in vivo screening and efficacy evaluation.
With its strong clinical correlation to human respiratory conditions, this model serves as a valuable platform for research in respiratory diseases.
Reference:
https://www.hokudo.co.jp/4-1_kobetsushiken.html
Hokudo Co.,Ltd. conducts spinal cord injury model in rats using MASCIS Impactor to create controlled injuries.
Motor function is quantitatively assessed using the BBB (Basso, Beattie, Bresnahan) score, allowing researchers to monitor neural recovery over time.
This approach supports the evaluation of potential therapeutic drugs for nervous system repair and regeneration.
Reference:
https://www.hokudo.co.jp/4-1_kobetsushiken.html
| Address | 4-28, Hachiken 9-jo Nishi 10-chome, Nishi-ku, Sapporo, Hokkaido, Japan |
|---|---|
| Tel | 011-641-7507 |
| Website | https://www.hokudo.co.jp |
In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D.
In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening.
Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.